AAPL 237.5 1.809% MSFT 426.24 2.5429% NVDA 135.5501 2.8765% GOOGL 195.37 3.0107% GOOG 196.84 3.0306% AMZN 222.4999 2.1767% META 619.8747 4.3121% AVGO 227.51 1.2506% TSLA 420.01 5.9668% TSM 205.23 1.8764% LLY 746.665 0.2356% V 316.69 2.4588% JPM 252.363 1.9772% UNH 544.335 0.1094% NVO 82.94 2.168% WMT 91.475 0.7545% LVMUY 131.3 -2.0515% XOM 111.354 1.4892% LVMHF 656.0 -1.7131% MA 520.8 2.3143%
Last update at 2025-01-16T14:55:00Z
BioCryst Pharmaceuticals, Inc. (BCRX) Surpasses Revenue Expectations by $11 Million in Q2
Wed 09 Oct 24, 12:03 PM7 Small-Cap Stocks to Buy for Large-Scale Gains
Tue 30 Jul 24, 04:25 PMBioCryst Pharmaceuticals Insiders Added US$1.05m Of Stock To Their Holdings
Wed 26 Jun 24, 04:30 PMBreakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Income before tax | -244.38400M | -181.80900M | -182.81400M | -108.89700M | -101.25200M |
Minority interest | - | - | - | - | - |
Net income | -247.11700M | -184.06200M | -196.56700M | -120.06500M | -101.25200M |
Selling general administrative | 159.37M | 118.82M | 67.93M | 37.12M | 29.51M |
Selling and marketing expenses | - | - | - | - | - |
Gross profit | 264.23M | 149.91M | 16.14M | 44.73M | 20.18M |
Reconciled depreciation | 1.44M | 0.78M | 0.75M | 0.72M | 0.77M |
Ebit | -148.43500M | -177.72000M | -174.75700M | -99.45500M | -92.73800M |
Ebitda | -143.30800M | -177.65800M | -165.33700M | -97.52200M | -91.96800M |
Depreciation and amortization | 5.13M | 0.06M | 9.42M | 1.93M | 0.77M |
Non operating income net other | - | 55.14M | -2.97600M | 2.45M | 2.14M |
Operating income | -148.43500M | -177.72000M | -174.75700M | -99.45500M | -94.22000M |
Other operating expenses | 419.26M | 334.89M | 192.57M | 148.29M | 114.87M |
Interest expense | 99.09M | 59.29M | 14.50M | 11.89M | 9.18M |
Tax provision | 2.73M | 2.25M | - | - | - |
Interest income | 5.13M | 0.06M | 9.42M | 1.93M | 2.25M |
Net interest income | -93.96500M | -59.23200M | -5.08100M | -9.95900M | -6.92400M |
Extraordinary items | - | - | - | - | - |
Non recurring | - | - | 0.13M | 0.38M | 0.47M |
Other items | - | - | - | - | - |
Income tax expense | 2.73M | 2.25M | 13.75M | 11.17M | 2.14M |
Total revenue | 270.83M | 157.17M | 17.81M | 48.84M | 20.65M |
Total operating expenses | 412.67M | 327.63M | 190.89M | 144.19M | 114.40M |
Cost of revenue | 6.59M | 7.26M | 1.68M | 4.10M | 0.47M |
Total other income expense net | -95.94900M | -4.08900M | -8.05700M | -9.44200M | -0.10800M |
Discontinued operations | - | - | - | - | - |
Net income from continuing ops | -247.11700M | -184.06200M | -192.23400M | -108.89700M | -101.25200M |
Net income applicable to common shares | -247.11600M | -184.06200M | -182.81400M | -108.89700M | -101.25200M |
Preferred stock and other adjustments | - | - | - | - | - |
Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
Total assets | 516.96M | 550.00M | 588.15M | 334.71M | 175.28M |
Intangible assets | - | - | - | - | - |
Earning assets | - | - | - | - | - |
Other current assets | 19.54M | 12.59M | 9.99M | 5.53M | 4.42M |
Total liab | 972.49M | 844.60M | 695.14M | 353.98M | 137.03M |
Total stockholder equity | -455.52800M | -1454.62100M | -1207.50400M | -1023.44200M | -840.62800M |
Deferred long term liab |